AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 36606571 — intervention group
Group type: COMPARATOR
Intervention: Control group (EUS-FNA without CH-EUS MASTER guidance)
Number of subjects: 0
Study 36606664 — intervention group
Group type: EXPERIMENTAL
Intervention: FOLFOX (5-fluorouracil, leucovorin, oxaliplatin)
Number of subjects: 0
Study 36606801 — intervention group
Group type: EXPERIMENTAL
Intervention: Subjective mental health rating
Number of subjects: 850
Study 36606801 — intervention group
Group type: EXPERIMENTAL
Intervention: Subjective physical health rating
Number of subjects: 850
Study 36606801 — intervention group
Group type: EXPERIMENTAL
Intervention: EQ-5D Visual Analog Scale
Number of subjects: 850
Study 36606801 — intervention group
Group type: EXPERIMENTAL
Intervention: Stepwise regression with additional covariates
Number of subjects: 850
Study 36607429 — intervention group
Group type: EXPERIMENTAL
Intervention: Zolbetuximab alone (n=5)
Number of subjects: 28
Study 36607429 — intervention group
Group type: EXPERIMENTAL
Intervention: Zolbetuximab + Zoledronic Acid (ZA) + Intermediate-dose IL-2 (3 mIU) (n=7)
Number of subjects: 28
Study 36607429 — intervention group
Group type: EXPERIMENTAL
Intervention: Zolbetuximab + Zoledronic Acid (ZA) + Low-dose IL-2 (1 mIU) (n=9)
Number of subjects: 28
Study 36607429 — intervention group
Group type: EXPERIMENTAL
Intervention: Zolbetuximab + Zoledronic Acid (ZA) + IL-2 (both doses)
Number of subjects: 28
Study 36607429 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical efficacy population (n=19)
Number of subjects: 28
Study 36607533 — intervention group
Group type: EXPERIMENTAL
Intervention: High-frequency percussive ventilation (HFPV) for 10 minutes
Number of subjects: 0
Study 36607533 — intervention group
Group type: EXPERIMENTAL
Intervention: High-frequency percussive ventilation (HFPV)
Number of subjects: 0
Study 36607544 — intervention group
Group type: EXPERIMENTAL
Intervention: CMAB008 (an Infliximab Biosimilar)
Number of subjects: 0
Study 36607544 — intervention group
Group type: COMPARATOR
Intervention: Remicade
Number of subjects: 0
Study 36607707 — intervention group
Group type: EXPERIMENTAL
Intervention: Know@Home mobile app
Number of subjects: 2093
Study 36607707 — intervention group
Group type: COMPARATOR
Intervention: Referral to web resources
Number of subjects: 2093
Study 36607707 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV self-tests (HIVSTs) provided to all participants
Number of subjects: 2093
Study 36607707 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile app
Number of subjects: 2093
Study 36607735 — intervention group
Group type: EXPERIMENTAL
Intervention: PVX2 vaccination (twice with HPV16-targeting pNGVL4a-Sig/E7(detox)/HSP70 plasmid and once with TA-CIN protein)
Number of subjects: 12
Study 36607735 — intervention group
Group type: EXPERIMENTAL
Intervention: PVX2 vaccination
Number of subjects: 12
Study 36607832 — intervention group
Group type: EXPERIMENTAL
Intervention: Low EQ-5D index
Number of subjects: 2205
Study 36607832 — intervention group
Group type: EXPERIMENTAL
Intervention: Low VAS score
Number of subjects: 2205
Study 36607849 — intervention group
Group type: EXPERIMENTAL
Intervention: Low bone mineral density (BMD)
Number of subjects: 40
Study 36607849 — intervention group
Group type: COMPARATOR
Intervention: Normal bone mineral density (BMD)
Number of subjects: 40
Study 36607971 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-acute care (PAC) with comprehensive geriatric assessment (CGA), exercise, nutrition education, and medicinal adjustments for two to four weeks
Number of subjects: 254
Study 36607971 — intervention group
Group type: COMPARATOR
Intervention: Control group receiving only comprehensive geriatric assessment (CGA)
Number of subjects: 254
Study 36608001 — intervention group
Group type: EXPERIMENTAL
Intervention: Combat Application Tourniquet (CAT) applied to each thigh, tightened until no pulse is felt in the lower extremity.
Number of subjects: 0
Study 36608033 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluorescence lifetime imaging ophthalmoscopy (FLIO) with 473 nm laser excitation
Number of subjects: 141
Study 36608305 — intervention group
Group type: EXPERIMENTAL
Intervention: Lenvatinib and Pembrolizumab
Number of subjects: 0
Study 36608308 — intervention group
Group type: EXPERIMENTAL
Intervention: GEN-1 (neoadjuvant single-arm phase IB study)
Number of subjects: 18
Study 36608308 — intervention group
Group type: COMPARATOR
Intervention: Standard neoadjuvant chemotherapy (historical control arm)
Number of subjects: 18
Study 36608310 — intervention group
Group type: EXPERIMENTAL
Intervention: ibrutinib 420 mg once daily plus prednisone (1 mg/kg once daily)
Number of subjects: 193
Study 36608310 — intervention group
Group type: COMPARATOR
Intervention: placebo plus prednisone
Number of subjects: 193
Study 36608310 — intervention group
Group type: EXPERIMENTAL
Intervention: ibrutinib-prednisone
Number of subjects: 193
Study 36608310 — intervention group
Group type: COMPARATOR
Intervention: placebo-prednisone
Number of subjects: 193
Study 36608310 — intervention group
Group type: EXPERIMENTAL
Intervention: ibrutinib treatment
Number of subjects: 193
Study 36608320 — intervention group
Group type: EXPERIMENTAL
Intervention: Encorafenib 450 mg once daily and binimetinib 45 mg twice daily
Number of subjects: 12
Study 36608383 — intervention group
Group type: EXPERIMENTAL
Intervention: Interval cytoreductive surgery (ICS) followed by hyperthermic intraperitoneal chemotherapy (HIPEC)
Number of subjects: 0
Study 36608383 — intervention group
Group type: COMPARATOR
Intervention: Interval cytoreductive surgery (ICS)
Number of subjects: 0
Study 36608382 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet plus physical activity intervention delivered via centralized telephone-based health coaching
Number of subjects: 1205
Study 36608382 — intervention group
Group type: COMPARATOR
Intervention: Control condition (not specified)
Number of subjects: 1205
Study 36608413 — intervention group
Group type: EXPERIMENTAL
Intervention: Reflexology
Number of subjects: 300
Study 36608413 — intervention group
Group type: EXPERIMENTAL
Intervention: Sucrose (24% solution)
Number of subjects: 300
Study 36608413 — intervention group
Group type: EXPERIMENTAL
Intervention: Kangaroo care
Number of subjects: 300
Study 36608413 — intervention group
Group type: EXPERIMENTAL
Intervention: Classical music
Number of subjects: 300
Study 36608413 — intervention group
Group type: COMPARATOR
Intervention: Nonpharmacologic methods (including reflexology, sucrose, kangaroo care, classical music)
Number of subjects: 300
Study 36608435 — intervention group
Group type: EXPERIMENTAL
Intervention: SAPIEN 3 Transcatheter Heart Valve (THV) implantation
Number of subjects: 58
Study 36608483 — intervention group
Group type: EXPERIMENTAL
Intervention: MDD-PRS (Polygenic Risk Score for Major Depressive Disorder)
Number of subjects: 443
Study 36608945 — intervention group
Group type: EXPERIMENTAL
Intervention: Community gardening intervention (receiving a community garden plot)
Number of subjects: 291
Study 36608945 — intervention group
Group type: COMPARATOR
Intervention: Control group (remained on waiting list and did not garden)
Number of subjects: 291
Study 36609028 — intervention group
Group type: COMPARATOR
Intervention: ADHD diagnosis
Number of subjects: 6993
Study 36609028 — intervention group
Group type: COMPARATOR
Intervention: ADHD symptoms
Number of subjects: 6993
Study 36609028 — intervention group
Group type: COMPARATOR
Intervention: Control (absence of ADHD)
Number of subjects: 6993
Study 36609038 — intervention group
Group type: EXPERIMENTAL
Intervention: DCB-based treatment
Number of subjects: 254
Study 36609038 — intervention group
Group type: COMPARATOR
Intervention: DES-only treatment
Number of subjects: 254
Study 36609046 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal Glyceryl Trinitrate Patches
Number of subjects: 0
Study 36609046 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 36609057 — intervention group
Group type: EXPERIMENTAL
Intervention: Heart Rate (HR)
Number of subjects: 60
Study 36609057 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical Pleth Index (SPI)
Number of subjects: 60
Study 36609057 — intervention group
Group type: EXPERIMENTAL
Intervention: Pupillary Pain Index (PPI)
Number of subjects: 60
Study 36609057 — intervention group
Group type: EXPERIMENTAL
Intervention: Nociception Level (NOL)
Number of subjects: 60
Study 36609057 — intervention group
Group type: EXPERIMENTAL
Intervention: Multivariable predictor combining NOL with ASA physical status and regional anaesthesia use
Number of subjects: 60
Study 36609101 — intervention group
Group type: EXPERIMENTAL
Intervention: Super high-pressure balloon
Number of subjects: 80
Study 36609101 — intervention group
Group type: COMPARATOR
Intervention: Intravascular lithotripsy (IVL)
Number of subjects: 80
Study 36609226 — intervention group
Group type: EXPERIMENTAL
Intervention: General Anesthesia Group (GAG, n=18)
Number of subjects: 46
Study 36609226 — intervention group
Group type: COMPARATOR
Intervention: Regional Anesthesia Group (RAG, n=28)
Number of subjects: 46
Study 36609226 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (GAG and RAG)
Number of subjects: 46
Study 36609248 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient Navigation Intervention
Number of subjects: 24281
Study 36609257 — intervention group
Group type: EXPERIMENTAL
Intervention: Information about the acute illness
Number of subjects: 7488
Study 36609257 — intervention group
Group type: EXPERIMENTAL
Intervention: Age, gender, and geriatric characteristics
Number of subjects: 7488
Study 36609257 — intervention group
Group type: EXPERIMENTAL
Intervention: Decisions to withhold LST
Number of subjects: 7488
Study 36609257 — intervention group
Group type: EXPERIMENTAL
Intervention: Decisions to withdraw LST
Number of subjects: 7488
Study 36609279 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent Preventive Treatment of malaria in schoolchildren (IPTsc) using dihydroartemisinin-piperaquine (DP) given three times a year in four-month intervals.
Number of subjects: 24
Study 36609279 — intervention group
Group type: COMPARATOR
Intervention: Standard of care (control)
Number of subjects: 24
Study 36609335 — intervention group
Group type: EXPERIMENTAL
Intervention: Teacher training programme and mindfulness programme delivered to students
Number of subjects: 1100
Study 36609335 — intervention group
Group type: COMPARATOR
Intervention: Education as usual (Control)
Number of subjects: 1100
Study 36609349 — intervention group
Group type: EXPERIMENTAL
Intervention: Shared Decision Engagement System (SharES) with iCanDecide +/- emotional support module
Number of subjects: 700
Study 36609349 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinician Dashboard reviewed by surgeons/clinicians
Number of subjects: 700
Study 36609389 — intervention group
Group type: EXPERIMENTAL
Intervention: Palbociclib plus letrozole plus trastuzumab (PLT)
Number of subjects: 26
Study 36609655 — intervention group
Group type: EXPERIMENTAL
Intervention: Somatostatin analogues (SSA)
Number of subjects: 23
Study 36609655 — intervention group
Group type: EXPERIMENTAL
Intervention: Somatostatin analogues (SSA) + Pegvisomant (PEG)
Number of subjects: 23
Study 36609655 — intervention group
Group type: EXPERIMENTAL
Intervention: Pegvisomant (PEG)
Number of subjects: 23
Study 36609807 — intervention group
Group type: EXPERIMENTAL
Intervention: CCNU/TMZ
Number of subjects: 1
Study 36609807 — intervention group
Group type: COMPARATOR
Intervention: TMZ
Number of subjects: 1
Study 36609834 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-Task Training Group (MTTG)
Number of subjects: 42
Study 36609834 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-Task Training Group (STTG)
Number of subjects: 42
Study 36609834 — intervention group
Group type: COMPARATOR
Intervention: Control Group (CG)
Number of subjects: 42
Study 36609978 — intervention group
Group type: EXPERIMENTAL
Intervention: VDR rs7975232 polymorphism
Number of subjects: 151
Study 36609978 — intervention group
Group type: EXPERIMENTAL
Intervention: ACC haplotype (order of rs731236, rs7975232, rs1544410)
Number of subjects: 151
Study 36609978 — intervention group
Group type: EXPERIMENTAL
Intervention: rs7975232 CC genotype
Number of subjects: 151
Study 36610390 — intervention group
Group type: EXPERIMENTAL
Intervention: AZD1222 vaccination
Number of subjects: 3058
Study 36610464 — intervention group
Group type: EXPERIMENTAL
Intervention: Icatibant (30 mg doses/d for 3 consecutive days plus standard care)
Number of subjects: 73
Study 36610464 — intervention group
Group type: COMPARATOR
Intervention: Standard care alone (Control)
Number of subjects: 73
Study 36610886 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative intensity-modulated radiotherapy (IMRT)
Number of subjects: 3203
Study 36610886 — intervention group
Group type: COMPARATOR
Intervention: No postoperative IMRT
Number of subjects: 3203
Study 36610891 — intervention group
Group type: EXPERIMENTAL
Intervention: Sunitinib (monotherapy or combined with local treatment)
Number of subjects: 62
Study 36611210 — intervention group
Group type: EXPERIMENTAL
Intervention: Liberal transfusion strategy (maintaining hemoglobin concentrations greater than 9 g/dL)
Number of subjects: 794
Study 36611210 — intervention group
Group type: COMPARATOR
Intervention: Restrictive transfusion strategy (maintaining hemoglobin concentrations greater than 7 g/dL)
Number of subjects: 794
Study 36611210 — intervention group
Group type: EXPERIMENTAL
Intervention: Liberal transfusion strategy
Number of subjects: 794
Study 36611210 — intervention group
Group type: COMPARATOR
Intervention: Restrictive transfusion strategy
Number of subjects: 794
Study 36611211 — intervention group
Group type: EXPERIMENTAL
Intervention: Early nutrition support (< 48 h)
Number of subjects: 1206
Study 36611211 — intervention group
Group type: EXPERIMENTAL
Intervention: Early enteral nutrition
Number of subjects: 1206
Study 36611211 — intervention group
Group type: EXPERIMENTAL
Intervention: Early parenteral nutrition
Number of subjects: 1206
Study 36611211 — intervention group
Group type: COMPARATOR
Intervention: No early nutrition
Number of subjects: 1206
Study 36611312 — intervention group
Group type: EXPERIMENTAL
Intervention: MRD-positive B-ALL patients
Number of subjects: 267
Study 36611312 — intervention group
Group type: COMPARATOR
Intervention: MRD-negative B-ALL patients
Number of subjects: 267
Study 36611327 — intervention group
Group type: COMPARATOR
Intervention: Healthy control group (C)
Number of subjects: 143
Study 36611550 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational interviewing (MI) intervention
Number of subjects: 50
Study 36611550 — intervention group
Group type: COMPARATOR
Intervention: Attention group (control)
Number of subjects: 50
Study 36612650 — intervention group
Group type: EXPERIMENTAL
Intervention: Monthly telephonic interventions based on motivational interviewing and collaborative care strategies
Number of subjects: 384
Study 36612650 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 384
Study 36612844 — intervention group
Group type: EXPERIMENTAL
Intervention: Training programme for developing social and personal skills
Number of subjects: 0
Study 36612844 — intervention group
Group type: COMPARATOR
Intervention: Matched individuals not participating in the training
Number of subjects: 0
Study 36614923 — intervention group
Group type: EXPERIMENTAL
Intervention: onabotulinumtoxinA
Number of subjects: 183
Study 36614923 — intervention group
Group type: EXPERIMENTAL
Intervention: gabapentin
Number of subjects: 183
Study 36614923 — intervention group
Group type: EXPERIMENTAL
Intervention: oral preventive drugs
Number of subjects: 183
Study 36614923 — intervention group
Group type: EXPERIMENTAL
Intervention: oral preventive drugs and onabotulinumtoxinA
Number of subjects: 183
Study 36614948 — intervention group
Group type: EXPERIMENTAL
Intervention: V-01D-351
Number of subjects: 56
Study 36614948 — intervention group
Group type: EXPERIMENTAL
Intervention: BV-01-B5
Number of subjects: 56
Study 36614948 — intervention group
Group type: EXPERIMENTAL
Intervention: V-01
Number of subjects: 56
Study 36614948 — intervention group
Group type: COMPARATOR
Intervention: ICV
Number of subjects: 56
Study 36615077 — intervention group
Group type: EXPERIMENTAL
Intervention: Small Step early intervention program
Number of subjects: 11
Study 36615174 — intervention group
Group type: EXPERIMENTAL
Intervention: Aronia supplementation (150 mg anthocyanins daily)
Number of subjects: 109
Study 36615174 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 109
Study 36617389 — intervention group
Group type: COMPARATOR
Intervention: Fixed dose of insulin for a fixed range of carbohydrates (FD group)
Number of subjects: 24
Study 36617389 — intervention group
Group type: EXPERIMENTAL
Intervention: Precise dose of insulin for a precise number of carbohydrates using an insulin-to-carbohydrate ratio (ICR group)
Number of subjects: 24
Study 36617391 — intervention group
Group type: EXPERIMENTAL
Intervention: PROGRESS-CTO perforation risk score
Number of subjects: 4566
Study 36617406 — intervention group
Group type: EXPERIMENTAL
Intervention: Prefrail (defined by Fried phenotype)
Number of subjects: 19114
Study 36617406 — intervention group
Group type: EXPERIMENTAL
Intervention: Frail (defined by Fried phenotype)
Number of subjects: 19114
Study 36617406 — intervention group
Group type: EXPERIMENTAL
Intervention: Frailty (assessed by Fried phenotype and FI)
Number of subjects: 19114
Study 36617410 — intervention group
Group type: EXPERIMENTAL
Intervention: High-frequency spinal cord stimulation (HF-SCS)
Number of subjects: 50
Study 36617410 — intervention group
Group type: COMPARATOR
Intervention: Low-frequency spinal cord stimulation (LF-SCS)
Number of subjects: 50
Study 36617413 — intervention group
Group type: EXPERIMENTAL
Intervention: EIoT-ergo group
Number of subjects: 35
Study 36617554 — intervention group
Group type: EXPERIMENTAL
Intervention: GD2-specific 4SCAR-T cells (infused through intravenous administration alone or combined with intracavitary administration)
Number of subjects: 8
Study 36617554 — intervention group
Group type: EXPERIMENTAL
Intervention: GD2-specific 4SCAR-T cells
Number of subjects: 8
Study 36617560 — intervention group
Group type: EXPERIMENTAL
Intervention: Rezivertinib (BPI-7711) 180 mg orally once daily
Number of subjects: 43
Study 36617561 — intervention group
Group type: EXPERIMENTAL
Intervention: Prenatal social support measured using the ENRICHD Social Support Inventory (ESSI)
Number of subjects: 301
Study 36617729 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower-extremity perfusion assessment (LEPA) model
Number of subjects: 57
Study 36617848 — intervention group
Group type: EXPERIMENTAL
Intervention: Conservative treatment for midportion Achilles tendinopathy
Number of subjects: 54
Study 36617964 — intervention group
Group type: EXPERIMENTAL
Intervention: Attention Bias Modification (ABM)
Number of subjects: 101
Study 36617964 — intervention group
Group type: COMPARATOR
Intervention: Sham condition
Number of subjects: 101
Study 36618438 — intervention group
Group type: EXPERIMENTAL
Intervention: Fecal microbiota transplantation (FMT)
Number of subjects: 55
Study 36618582 — intervention group
Group type: EXPERIMENTAL
Intervention: 18 G Tuohy needle
Number of subjects: 40
Study 36618582 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 G Tuohy needle
Number of subjects: 40
Study 36618582 — intervention group
Group type: COMPARATOR
Intervention: Loss of Resistance Technique (LORT)
Number of subjects: 40
Study 36618582 — intervention group
Group type: COMPARATOR
Intervention: Fluoroscopy only method
Number of subjects: 40
Study 36618690 — intervention group
Group type: EXPERIMENTAL
Intervention: Mediterranean diet pattern (MDP) with nutrition education
Number of subjects: 0
Study 36618690 — intervention group
Group type: EXPERIMENTAL
Intervention: Mediterranean diet pattern (MDP)
Number of subjects: 0
Study 36618749 — intervention group
Group type: EXPERIMENTAL
Intervention: Comics-based intervention
Number of subjects: 35
Study 36618900 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibrutinib 560 mg once daily, Lenalidomide 20 mg or 25 mg once daily on Days 1-21 of each 28-day cycle, Rituximab 375 mg/m2
Number of subjects: 89
Study 36618900 — intervention group
Group type: EXPERIMENTAL
Intervention: Adverse events (AEs)
Number of subjects: 89
Study 36618925 — intervention group
Group type: EXPERIMENTAL
Intervention: Qishen granules
Number of subjects: 0
Study 36618925 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 36619318 — intervention group
Group type: EXPERIMENTAL
Intervention: Periodic fasting (n=73, 35.6%) for 40.4±20.6 years prior to COVID-19 diagnosis.
Number of subjects: 205
Study 36619318 — intervention group
Group type: COMPARATOR
Intervention: Non-fasters (n=132, 64.4%) who did not engage in periodic fasting.
Number of subjects: 205
Study 36619318 — intervention group
Group type: EXPERIMENTAL
Intervention: Periodic fasting (n=73, 35.6%)
Number of subjects: 205
Study 36619318 — intervention group
Group type: COMPARATOR
Intervention: Non-fasters (n=132, 64.4%)
Number of subjects: 205
Study 36619332 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily intake of 57 g Jarlsberg cheese (J-group)
Number of subjects: 66
Study 36619332 — intervention group
Group type: COMPARATOR
Intervention: Daily intake of 25-50 g Camembert (C-group)
Number of subjects: 66
Study 36619332 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily intake of 57 g Jarlsberg cheese (after switching from C-group)
Number of subjects: 66
Study 36619619 — intervention group
Group type: EXPERIMENTAL
Intervention: Functionality-based writing tasks
Number of subjects: 451
Study 36619619 — intervention group
Group type: COMPARATOR
Intervention: Creative writing tasks (control)
Number of subjects: 451
Study 36619630 — intervention group
Group type: EXPERIMENTAL
Intervention: Femoral arterial site for MAP measurement
Number of subjects: 80
Study 36619630 — intervention group
Group type: COMPARATOR
Intervention: Radial arterial site for MAP measurement
Number of subjects: 80
Study 36619630 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose norepinephrine (≥0.3 μg/kg/min)
Number of subjects: 80
Study 36619630 — intervention group
Group type: EXPERIMENTAL
Intervention: Norepinephrine (≥0.1 μg/kg/min)
Number of subjects: 80
Study 36619856 — intervention group
Group type: EXPERIMENTAL
Intervention: Alemtuzumab
Number of subjects: 811
Study 36620297 — intervention group
Group type: EXPERIMENTAL
Intervention: Inactivated COVID-19 vaccine
Number of subjects: 157
Study 36620297 — intervention group
Group type: COMPARATOR
Intervention: Health controls (HC)
Number of subjects: 157
Study 36620354 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital lifestyle intervention group (DIGI)
Number of subjects: 2907
Study 36620354 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 2907
Study 36620625 — intervention group
Group type: EXPERIMENTAL
Intervention: Statins
Number of subjects: 3831
Study 36620625 — intervention group
Group type: EXPERIMENTAL
Intervention: CRP levels
Number of subjects: 3831
Study 36620625 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 3831